Frontlight ResearchEarly access
Not yet recruitingNo phase
Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B
Key facts
- Who runs it
- University of Ulm
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 15 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 30 Jun 2029
- Type of study
- Observational
- Treatments tested
- Metabolic and epigenetic characterization of mothers and fetuses
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Pregnant women from gestational week 13+0
- No known underlying medical conditions i
- No known underlying diseases
- Understanding and voluntary signing of a consent form before study- related examinations
Who cannot take part
- Regular use of medication during pregnancy
- Drug and/or alcohol abuse
- Type 1 or type 2 diabetes mellitus
- Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
- Current depression or other psychiatric disorders
- Eating disorders
- Pre-existing cardiovascular disease
- Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion
- Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
- Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
- Transaminase elevation of 2 times the upper norm
- Age < 18 years
- C-reactive protein > 10 mg/l
- No consent to be informed about incidentally discovered pathological findings
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.
Read full original descriptionShow less
The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.
The group in the trial
- Pregnant women
Metabolic and epigenetic characterization
Treatment: Metabolic and epigenetic characterization of mothers and fetuses
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 November 2026